|
Valoración de DCF de Nektar Therapeutics (NKTR)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Nektar Therapeutics (NKTR) Bundle
¡Agilice su análisis y mejore la precisión con nuestra calculadora DCF NKTR (Nektar Therapeutics)! Equipado con datos reales de Nektar y supuestos personalizables, esta herramienta le permite pronosticar, evaluar y valorar NKTR como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.6 | 152.9 | 101.9 | 92.1 | 90.1 | 87.5 | 84.9 | 82.4 | 80.0 | 77.7 |
| Revenue Growth, % | 0 | 33.41 | -33.36 | -9.67 | -2.1 | -2.93 | -2.93 | -2.93 | -2.93 | -2.93 |
| EBITDA | -382.7 | -394.3 | -463.0 | -323.9 | -243.1 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| EBITDA, % | -333.89 | -257.87 | -454.3 | -351.82 | -269.75 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 11.0 | 12.5 | 13.0 | 12.2 | 7.8 | 9.2 | 8.9 | 8.6 | 8.4 | 8.1 |
| Depreciation, % | 9.6 | 8.17 | 12.76 | 13.25 | 8.67 | 10.49 | 10.49 | 10.49 | 10.49 | 10.49 |
| EBIT | -393.7 | -406.8 | -476.0 | -336.1 | -250.9 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| EBIT, % | -343.49 | -266.05 | -467.06 | -365.08 | -278.42 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1,324.9 | 1,061.9 | 734.0 | 505.0 | 303.6 | 87.5 | 84.9 | 82.4 | 80.0 | 77.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 36.8 | 38.9 | 22.5 | 6.0 | 2.3 | 15.5 | 15.0 | 14.6 | 14.2 | 13.8 |
| Account Receivables, % | 32.11 | 25.43 | 22.07 | 6.5 | 2.5 | 17.72 | 17.72 | 17.72 | 17.72 | 17.72 |
| Inventories | 12.7 | 15.3 | 15.8 | 19.2 | 16.1 | 13.2 | 12.8 | 12.4 | 12.0 | 11.7 |
| Inventories, % | 11.05 | 10 | 15.51 | 20.86 | 17.87 | 15.06 | 15.06 | 15.06 | 15.06 | 15.06 |
| Accounts Payable | 19.2 | 22.1 | 9.7 | 13.0 | 9.8 | 11.5 | 11.2 | 10.9 | 10.5 | 10.2 |
| Accounts Payable, % | 16.78 | 14.48 | 9.56 | 14.1 | 10.93 | 13.17 | 13.17 | 13.17 | 13.17 | 13.17 |
| Capital Expenditure | -26.3 | -7.3 | -15.0 | -5.7 | -.9 | -8.7 | -8.4 | -8.2 | -7.9 | -7.7 |
| Capital Expenditure, % | -22.93 | -4.75 | -14.71 | -6.17 | -0.95981 | -9.9 | -9.9 | -9.9 | -9.9 | -9.9 |
| Tax Rate, % | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 |
| EBITAT | -394.2 | -407.3 | -476.5 | -339.0 | -250.7 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -439.8 | -403.8 | -475.0 | -316.2 | -240.1 | -95.6 | -83.9 | -81.5 | -79.1 | -76.8 |
| WACC, % | 9.39 | 9.39 | 9.39 | 9.39 | 9.38 | 9.38 | 9.38 | 9.38 | 9.38 | 9.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -324.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -78 | |||||||||
| Terminal Value | -1,060 | |||||||||
| Present Terminal Value | -677 | |||||||||
| Enterprise Value | -1,001 | |||||||||
| Net Debt | 210 | |||||||||
| Equity Value | -1,211 | |||||||||
| Diluted Shares Outstanding, MM | 190 | |||||||||
| Equity Value Per Share | -6.37 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NKTR financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Nektar Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Pre-Loaded Data: Nektar Therapeutics’ historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Edit WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: See Nektar Therapeutics’ intrinsic value recalculate in real time.
- Clear Visual Outputs: Dashboard charts display valuation results and key metrics.
- Built for Accuracy: A professional tool for analysts, investors, and finance experts.
How It Works
- 1. Open the Template: Download and open the Excel file containing Nektar Therapeutics (NKTR) preloaded data.
- 2. Edit Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV for Nektar Therapeutics (NKTR).
- 4. Test Scenarios: Evaluate various forecasts to explore different valuation outcomes for Nektar Therapeutics (NKTR).
- 5. Use with Confidence: Present professional valuation insights to support your investment decisions regarding Nektar Therapeutics (NKTR).
Why Choose This Calculator for Nektar Therapeutics (NKTR)?
- Accurate Data: Up-to-date Nektar Therapeutics financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants focused on Nektar Therapeutics.
- User-Friendly: Easy-to-navigate design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Nektar Therapeutics (NKTR) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Nektar Therapeutics (NKTR).
- Consultants: Deliver professional valuation insights on Nektar Therapeutics (NKTR) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like Nektar Therapeutics (NKTR) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Nektar Therapeutics (NKTR).
What the Template Contains
- Pre-Filled DCF Model: Nektar Therapeutics’ (NKTR) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Nektar Therapeutics’ (NKTR) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.